	US 11,952,597 B2
	*Compositions and methods relating to a mutant Clostridium difficile* toxin**
Jason Arnold Lotvin, Thiells, NY (US); Annaliesa Sybil Anderson, Upper Saddle River, NJ (US); Robert G. K. Donald, South Orange, NJ (US); Michael James Flint, Decatur, GA (US); Narender Kumar Kalyan, Ridgewood, NJ (US); Kathrin Ute Jansen, New York, NY (US); Maninder K. Sidhu, New City, NY (US); Justin Keith Moran, West Nyack, NY (US); Mark Edward Ruppen, Garnerville, NY (US); and Weiqiang Sun, Morristown, NJ (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Jul. 7, 2020, as Appl. No. 16/922,952.
Application 16/922,952 is a division of application No. 14/436,875, granted, now 10,787,652, previously published as PCT/IB2013/059183, filed on Oct. 7, 2013.
Claims priority of provisional application 61/716,605, filed on Oct. 21, 2012.
Prior Publication US 2021/0024903 A1, Jan. 28, 2021
Int. Cl. C12N 9/10 (2006.01); C07K 14/33 (2006.01); C12N 1/20 (2006.01)

CPC C12N 9/1051 (2013.01) [C07K 14/33 (2013.01); C12N 1/20 (2013.01)]

5 Claims

1. A method of eliciting an immune response in a mammal, comprising administering an effective amount of a composition comprising a lyophilized polypeptide comprising the amino acid sequence set forth in any one of SEQ ID NOs: 185-194; a saponin adjuvant; and a stabilizer selected from the group consisting of starch, dextran, sucrose, trehalose, lactose, and glucose; wherein the composition does not comprise formaldehyde; and wherein the method comprises administering at least two doses of the composition to the mammal.